Woody Joseph Fralin, serving as a director for AVITA Medical, Inc. (NASDAQ:RCEL), has executed a direct acquisition of the company's common equity. On June 9, 2026, Fralin secured 5,200 shares at a unit price of $4.00, resulting in a total transaction value of $20,800.
Following this acquisition, Fralin's direct ownership stake in AVITA Medical's common stock stands at 107,961 shares. This aggregate figure encompasses his holdings of unvested Restricted Stock Units (RSUs) in addition to the newly acquired shares.
The insider transaction takes place while AVITA Medical shares are trading at $4.13. The stock has demonstrated a 19% gain year-to-date, contrasting with a 32% decline observed over the trailing twelve-month period. Market analysis from InvestingPro suggests the equity may be trading below its calculated Fair Value. However, investors are cautioned by InvestingPro Tips regarding the stock's pronounced volatility. The platform identifies five additional key insights relevant to RCEL investors.
Concurrently, AVITA Medical released its first-quarter 2026 financial results, presenting a mixed operational profile. The company reported earnings per share (EPS) of -$0.35, falling short of the consensus forecast of -$0.29. This discrepancy represents a 20.69% miss against expectations. Conversely, revenue performance exceeded analyst projections, coming in at $19.3 million versus the anticipated $18.3 million. This top-line result generated a 5.46% revenue surprise, serving as a positive indicator amid the earnings shortfall.
No mergers or acquisitions were reported during this reporting period. Recent updates do not include analyst commentary regarding Avita Medical's stock valuation or outlook. These financial disclosures remain part of the company's ongoing reporting cycle.